Open AccessEmodin: One Main Ingredient of Shufeng Jiedu Capsule Reverses Chemoresistance of Lung Cancer Cells Through Inhibition of EMT
Author(s) -
Ying Yuan,
Qingwu Liao,
Mingming Xue,
Zifang Song,
Chaoyang Tong,
Zhengang Tao
Publication year - 2017
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000478754
Subject(s) - slug , western blot , apoptosis , epithelial–mesenchymal transition , flow cytometry , cancer cell , doxorubicin , mtt assay , biology , cancer research , chemistry , microbiology and biotechnology , pharmacology , cancer , biochemistry , metastasis , chemotherapy , genetics , gene
Chemoresistance has become a an important worldwide problem to cancer treatment. Understanding the mechanism of drug resistance is the key to solve this problem and improve the survival of the patient. Doxorubicin and its analogues are widely used as antitumor drugs but many doxorubicin resistant cases have been identified in recent years. Doxorubicin (Dox) resistance is a very serious phenomenon in lung cancer treatment. As we could show previously, Shufeng Jiedu Capsule (SFJDC) can effectively reverse H69AR cells resistance to Dox, thus, the present study was designed to explore the mechanism underlying the effects of the main ingredient Emodin on chemosensitivity of H69AR cells to Dox.